Iridium complex is a promising organic light-emitting diode material for next generation video displays that emits phosphorescence quenched by oxygen. We used this oxygen-quenching feature for imaging tumor hypoxia. Red light-emitting Ir(btp) 2 (acac) (BTP) presented hypoxia-dependent light emission in culture cell lines, whose intensity was in parallel with hypoxia-inducible factor-1α images. BTP was further applied to imaging five nude mouse transplanted with tumors. All tumors presented a bright BTP-emitting image even 5 minutes after injection. The minimal image recognition size was ∼2 mm in diameter. By morphologic examination and phosphorescence lifetime measurement, BTP appeared to localize to the tumor cells. Because BTP is easily modifiable, we synthesized BTP analogues with a longer excitation/emission wavelength. One of them, BTPHSA, depicted clear imaging from tumors transplanted 6 to 7 mm deep from the skin surface. We suggest that iridium complex materials have a vast potential for imaging hypoxic lesions such as tumor tissues. Cancer Res; 70(11); 4490-8. ©2010 AACR.
Introduction
Hypoxia is highly notable in tumor tissues (1, 2) , in which hypoxia-inducible factor (HIF)-1α is induced by inhibiting its degradation through the decrease in oxygen-sensing prolyl 4-hydroxylase activity (3, 4) . HIF-1α regulates a variety of gene expressions including vascular endothelial growth factor (VEGF) and glucose transporter (Glut)-1. Through HIF-1α-mediated gene expression, tumors are vascularized by VEGF to receive oxygen and nutrients for their growth in a hypoxic milieu (2) . Several hypoxia-associated probes have been developed for tumor imaging including nitroimidazole (5, 6) , Cu-diacetyl-bis(N 4 -methylthiosemicarbazone (7), and fluorodeoxyglucose (8) . They are used with radioisotope for visualization by positron emission tomography (PET).
An optical method was shown to directly detect oxygen in cells and tissues by using oxygen-dependent quenching of phosphorescence (9) . For this purpose, two groups of phosphorescent probes were developed: one is ruthenium(II) complexes and iridium(III) complexes (10) (11) (12) , and the other is metalloporphyrin complexes (13) (14) (15) . The difference of the two groups is primarily attributed to the phosphorescence lifetime, which is shorter for the former than for the latter. As an oxygen sensor, metalloporphyrins are too sensitive to oxygen quenching because of their long phosphorescence lifetime. Therefore, they have been modified by decorating "molecular coats" to adjust oxygen access to core porphyrins (14, 16, 17) . Furthermore, the molecular coats can protect the phosphor from albumin and give them their hydrophilic nature. However, their molecular size enlarges to over 2,000 Da exemplified by the paradium-porphyrin complex (13, 14) . Ruthenium(II) complex and iridium(III) complex were also used with binding to polymer or quantum dots (12, 18) . These large probes have been applied to measure oxygen pressure in microcapillary vessels (13, 14, 16) .
Iridium complexes possess highly phosphorescent and photostable properties that are required for use as organic light-emitting diode emitters. Furthermore, we are able to use various ligands to improve the photophysical and chemical properties for hypoxic tissue imaging. Because iridium complexes are relatively small in molecular size (600-800 Da) and lipophilic if not modified, they may be able to cross the cell membrane and measure intracellular oxygen pressure. In this study, we first used the red-emitting iridium complex Ir(btp) 2 (acac) [BTP; bis(2-(2′-benzothienyl)-pyridinato-N,C 3 ′)iridium(acetylacetonate); Fig. 1A ; ref. 19 ). The red phosphorescence is advantageous for tissue penetrance and its moderately long lifetime (5.8 μs) is favorable for oxygen-induced quenching. Based on these properties, we applied this phosphor for hypoxic tumor imaging without binding to any carriers. Because the excitation and emission wavelengths of BTP do not reach the near IR zone, we shifted them to a much longer zone by modification. We found that this iridium complex is easily modified for more desirable phosphorescent probes.
Materials and Methods

Physicochemical features of iridium complex
BTP was synthesized from IrCl 3 ·3H 2 O (Kanto) according to the procedure found in the literature (19) . A mixture of 2-(benzo[b]thiophen-2-yl)pyridine (460 mg, 2.2 mmol), IrCl 3 ·3H 2 O (390 mg, 1 mmol), 2-ethoxyethanol (30 mL), and distilled water (10 mL) was heated at reflux for 15 hours. After cooling, the precipitate formed was filtered to give a chloro-bridged dimer and washed thoroughly with methanol and n-hexane. To the mixture of the chloro-bridged dimer (260 mg, 0.2 mmol) and Na 2 CO 3 (170 mg, 1.6 mmol), 2-methoxyethanol (30 mL) and acetyl acetone (1.0 mL, 9.5 mmol) were added and then the slurry was refluxed for 2 hours. After the mixture was cooled down, the precipitate formed was collected by filtration and washed thoroughly with methanol and n-hexane. Yield was as follows: 180 mg (62%). Dimyristoyl-L-α-phosphatidylcholine (DMPC; Sigma 99%) was used for lipid membrane and liposome preparation. 1,2-Dichloroethane (DCE; Kishida, spectroscopic grade) and n-hexane (Kanto; fluorometric grade) were used without further purification. Deionized water was purified by using Millipore (MILLI-Q-LABO). Small unilamellar vesicles were prepared by using the ethanol injection method. The ethanolic solution of DMPC (3.0 × 10 −2 moldm −3 , 0.1 mL) was injected rapidly into Tris-HCl buffer (2.85 mL; pH 7.0) at 50°C. The incorporation of BTP into the small unilamellar vesicles was carried out by adding a stock solution of BTP (6.0 × 10
, 0.05 mL) in DMSO. The final concentration of the BTP probe was 1.0 × 10
. The solution was equilibrated for 1 hour above the phase transition temperature (23°C) of DMPC.
Human serum albumin (HSA; 96-99%) was purchased from Sigma. HSA solution in Tris-HCl buffer (pH 7.0) was bubbled with oxygen-nitrogen mixed gas to adjust the dissolved oxygen concentration and then a small amount of BTP solution in DMSO was added to the HSA solution. Final concentrations of BTP and HSA in Tris buffer/DMSO (98: 2, v/v) were 5 and 200 μmol/L, respectively. Oxygenquenching experiments were carried out for BTP dissolved in a bulk solution, DMPC membrane-incorporated BTP, and HSA-bound BTP. Nitrogen-oxygen mixed gas regulated with a mass-flow meter (HORIBA STEC; SEC-V110DM, PAC-D2) was bubbled through the sample solution for 20 minutes before luminescence measurement.
Absorption and emission spectra were measured with a UV/vis spectrophotometer (Jasco, Ubest-V550) and a spectrofluorimeter (Hitachi, F-4010), respectively. The emission spectrum was corrected for spectral sensitivity. Phosphorescence lifetime was measured with a time-correlated singlephoton counting fluorimeter (Edinburgh Analytic Instrument, FL-900CDT). A nanosecond-pulsed discharge lamp (pulse width, ∼1.0 ns; repetition rate, 40 kHz) filled with nitrogen gas was used for an excitation light source.
Cell culture and BTP uptake
We used four cell lines, human uterine cancer-derived HeLa, Chinese hamster ovary (CHO)-derived CHO, mouse oral squamous carcinoma-derived SCC-7, and human glioma-derived U251. We also used O 2 concentration-changeable multigas incubator MCO-5M (Sanyo). Cells were cultured in DMEM (Invitrogen) with 10% fetal bovine serum (FBS) at 37°C. The cells were cultured under four O 2 concentrations: 2.5, 5.0, 10, and 20% for 24 hours at 37°C. Then, BTP was added to the medium at a final concentration of 50 μmol/L for 1 hour for visualization (520-550 nm excitation/over 580 nm emission).
Tumor transplantation to nude mice
We conducted our animal experiments in accordance with the guidelines for the Care and Use of Laboratory Animals of the Medical Research Council of Gunma University. Tumor transplants were established in female athymic nude mice by injection of 5 × 10 6 SCC-7, human glioma-derived U87, human lymphoma-derived RAMOS, human colon carcinoma-derived HT-29, and mouse lung cancer-derived LL-2. Experiments with tumor-bearing mice were performed 2 weeks after the injection of tumor cells. To transplant 
In vivo imaging
Luminescence images of a whole mouse body and close-up image were obtained using the Maestro FL500 in vivo imaging system (CRi, Inc.). A band-pass filter from 520 to 550 nm and a long-pass filter over 580 nm were used for excitation and emission light, respectively. The tunable filter was automatically stepped in 10-nm increments from 550 to 800 nm, whereas the camera captured images at each wavelength interval with 1,500 ms exposure. Spectral fluorescence images consisting of autofluorescence spectra and BTP spectra were obtained and then unmixed, based on their spectral patterns using commercial software (Maestro software, CRi, Inc.). The spectra for unmixed images are shown in Fig. 3 (blue and sky-blue are auto-fluorescence; red is BTP spectra). The intensities of the BTP signal were automatically calculated with unmixed images by the Maestro software.
Measurement of oxygen partial pressure pO 2 in the tumors was measured with a needle-type polarographic oxygen electrode (PO2-150S, Eikou-kagaku Co. Ltd.). An oxygen electrode probe of a 200 μm diameter was inserted into tumors of immobilized mice without general anesthesia; then pO 2 was measured at 10 or more different points in each tumor; and the mean pO 2 was calculated. After the measurements, the tumors were excised and weighed.
BTP localization in tissues
The Olympus IV100 microscope was used for imaging BTP signals in tissues. Images were acquired with the IV100 imaging software (Olympus). A 488-nm argon laser and 586 to 615 nm band-pass filters were used for the excitation and emission of BTP. AngioSense 750 (VisEn Medical) was used to visualize blood vessels. A 748-nm laser and 770 nm long-pass filters were used for the excitation and emission of AngioSense 750.
In vivo lifetime measurement
In vivo phosphorescence lifetime measurement was performed for SCC-7 tumor-bearing mice with a time-correlated single photon counting fluorimeter. The excitation light (337 nm) from a nanosecond pulsed discharge lamp filled with nitrogen gas was collimated to the tumor area or normal tissues in each mouse after removing a part of the back skin and the phosphorescence at 620 nm was detected by a photomultiplier tube after passing through a monochromator.
Results
Photophysical properties of BTP complexes
To examine BTP phosphor quenching, we assumed two situations because of its lipophilic nature (Fig. 1A) : BTP in the lipid bilayer membrane and BTP bound to blood components exemplified by albumin. To test the first assumption, we measured its uptake into an artificial membrane composed of DMPC (1 mmol/L). Indeed, over 98% of BTP (10 μmol/L) was partitioned into the membrane at 35°C. We then investigated the photophysical properties of BTP in DMPC liposome and in DCE and n-hexane solutions. BTP in a deaerated DCE solution showed the first absorption maximum at 483 nm with a molar absorption coefficient of 6,100 M −1 cm −1 and it showed intense phosphorescence at 616 nm (Fig. 1B) . The phosphorescence quantum yield (Φ p 0 ) and lifetime (τ p 0 ) in a deaerated DCE solution (oxygen partial pressure pO 2 is assumed to be 0) were 0.32 and 5.8 μs, respectively, at room temperature. The phosphorescence quenching due to dissolved oxygen in solution or membrane can be examined by the following Stern-Volmer equation:
in which Φ p and τ p , respectively, are the phosphorescence quantum yield and lifetime, and k q is a bimolecular quenching rate constant (20) . At 35°C, the k q in n-hexane was 5. When τ p 0 = 5.3 μs (DMPC membrane) and tissue pO 2 = 60 mmHg are applied to this equation with the assumption that the quenching rate constants in the membrane and tissue are equal, Φ p 0 /Φ p comes to 4.8, indicating that BTP phosphorescence is quenched in the tissue pO 2 milieu of 60 mmHg. Because tissue pO 2 = 60 mmHg is not hypoxic (7), BTP is presumed to become phosphorescent at lower pO 2 , so BTP seems to be applicable to hypoxic tissue pO 2 estimation.
To test the second assumption that BTP is bound to albumin, we measured the oxygen-induced quenching rate constant (k q ) of the phosphorescence bound to albumin (200 μmol/L) in Tris-buffer/DMSO (98:2 v/v) solution at 35°C. Based on the Stern-Volmer analyses, the k q was obtained as 5.0 × 10 2 mmHg −1 s 1 along with τ p 0 = 4.3 μs (pO 2 = 0 mmHg) and τ p = 3.2 μs (pO 2 = 158 mmHg), which was in fact much smaller than that (1.2 × 10 4 mmHg −1 s −1 ) in the DMPC membrane. Thus, BTP phosphorescence is barely changeable between hypoxic and normoxic conditions in the presence of albumin, indicating that BTP is not efficient for oxygen quenching when it binds to albumin.
BTP to culture cells in a hypoxic milieu
We examined oxygen quenching in culture cells in a physiologic pO 2 milieu. If BTP binds to albumin in the culture medium and remains there without passing through the cell membrane, the cells would not emit enough phosphorescence. We placed four cell lines, human uterine cancerderived HeLa, CHO-derived CHO, mouse oral squamous carcinoma-derived SCC-7, and human glioma-derived U251 in a 20% O 2 culture condition. In normoxia, the three cell lines did not exhibit notable phosphorescence with BTP (50 μmol/L; Fig. 2A ). To the contrary, they emitted bright red phosphorescence in a 5% O 2 culture. We then observed the BTP phosphorescence in decreasing O 2 levels from 20% to 2.5% using SCC-7 cells (Fig. 2B, top) . With a decrease in O 2 concentration, the phosphorescence increased in an inverted manner. Likewise, HIF-1α was increasingly immunostained with a decrease in O 2 levels and appeared to be more concentrated in the nucleus than in the cytoplasm at 2.5% O 2 (Fig. 2B, bottom) . In accordance with this, HIF-1α protein gradually displayed an intensive band (Fig. 2C) .
Using the SCC-7 cells, we examined the uptake of BTP in the presence or absence of FBS or albumin in the culture medium. We added FBS or albumin to the SCC-7 culture medium for 2 hours then phosphorescence was evaluated under the fluorescent microscope. BTP or BTPHSA was poorly taken up into the cells in the absence of FBS or albumin. However, with the increase of FBS or albumin amounts in the culture medium, BTP analogues began to be taken up to the cells (Supplementary Fig. S1 ). Thus, BTP and its analogues are transported to the cells in an albumin-mediated manner and are released from albumin for their cellular uptake process.
BTP administration to tumor-bearing nude mice
For tumor imaging, we transplanted five culture cell lines into the lower thigh of nude mice: SCC-7, human gliomaderived U87, human lymphoma-derived RAMOS, human colon carcinoma-derived HT-29, and mouse lung cancerderived LL-2. The tumor size varied from 10 to 15 mm. Tumors tended to show undifferentiated features, whose histopathology is described in Supplementary Fig. S2 . With inserting an oxygen-monitoring probe 3-to 4-mm deep from the skin surface, we found that median pO 2 ranged from 18 to 21 mmHg (Supplementary Table S1 ). Thus, the pO 2 of each tumor was lower than that of end-capillary blood whose pO 2 ranges from 45 to 50 mmHg (2) . We looked at HIF-1α immunostaining in the five tumors. HIF-1α was well stained in SCC-7 and in HT-29 tumors, but was not well noted in the other tumors (Supplementary Fig. S2 ). We dissolved BTP in 10% DMSO due to its lipophilic feature. The BTP dose of 250 nmol/mouse was determined using SCC-7 tumor-bearing mice (data not shown). BTP (250 nmol/100 μL 10%DMSO) was injected from the tail vein under pentobarbital anesthesia. Each tumor-bearing mouse was placed in a dark box of the Maestro In-Vivo imaging System. Luminescence was detected 5 minutes after the injection in all five tumors and it increased gradually to a 1-hour point (Fig. 3) . The shape and position of the luminescence spectra emitted from the tumors were identical with those of the BTP phosphorescence spectrum (Fig. 1B) . Extratumor regions were virtually nonluminescent, but when anesthesia was overdosed, the forearm, perioral, and perinasal regions began to turn red. Furthermore, when the skin was pinched up and ligated with a thread, it became red within 1 minute after the ligation. Reversely, when the ligation was released, the skin turned to lose red-phosphorescence immediately ( Supplementary Fig. S3A ). Thus, BTP is distributed over the whole body and emits phosphorescence in which pO 2 decreases to a lower level.
We then determined the fate of BTP using SCC-7 tumors. The intensity of BTP was highest at 2 hours after the injection then declined gradually toward the 24-hours point when the tumor was not imaged (Supplementary Fig. S3B ).
Detection limit of tumor size and imaging depth
We examined the detection limit of BTP-imaged tumor size. SCC-7 cells were injected into nude mice and their tumor size was monitored daily. When the tumor reached 1 mm or more in diameter, we began to assess BTP imaging. When a tumor grew to 2 mm in diameter, its BTP imaging was reliably detected (Supplementary Fig. S4A ).
One of the drawbacks of luminescent imaging is the penetration limit of luminescence. We measured the penetration limit of BTP imaging by placing a 1.2-mm slice of pork ham on a BTP polyacrylamide gel. We could detect the BTP-imaging at a depth of 4.8 mm from the 20 nmol BTP gel and 7.2 mm from the 200 nmol BTP gel (Supplementary Fig. S4B, top) . Because actual BTP content in the tumor ranges around 5 to 8 nmol/g (data not shown) and a lump of polyacrylamide gel is close to 1 g, the detection limit is presumed to be ∼4 mm for BTP. Thus, to obtain much deeper tissue penetration, BTP should be modified for excitation by a red to near-IR wavelength.
In vivo imaging with a longer wavelength-shifted probe
To shift the absorption and emission spectra to longer wavelengths, we synthesized BTPH (Fig. 4A) , which has an extended π-electronic system compared with the benzothienyl-pyridinato group of the original BTP. Because the aqueous solubility of BTPH is extremely low, we further synthesized BTPHSA, a COOH derivative of BTPH (Fig. 4A) , to improve the solubility. The first absorption maximum of BTPH and BTPHSA is located at ∼550 nm and the phosphorescence maximum appears at 720 nm, i.e., in the near-IR region (Fig. 4A) . It is noted that the phosphorescence quantum yield of BTPH and BTPHSA is still large (0.30 and 0.24, respectively, in degassed DCE).
We then measured the penetration limit of phosphorescence from BTPHSA, using a pile of ham slices. Because the concentrtion of BTPHSA in the tumor was ∼3 nmol/g tumor weight, detection limit of phosphorescence seems to be ∼10 mm from the surface ( Supplementary Fig. S4B , bottom), which is deeper than that by BTP imaging. We next examined the detection wavelength for BTPHSA and BTP in subcutaneous SCC-7 tumor-bearing mice. The BTP-marked tumor was clearly visible by an excitation/ emission wavelength of 445 to 490 nm/580 nm, whereas the BTPHSA-marked tumor was brightly imaged by 575 to 605 nm/645 nm (Fig. 4B) . The maximal wavelength for BTP (615 nm) and for BTPHSA (720 nm) was longer than that used for this experiment. Thus, a combination of filter sets can be further improved. We lastly examined the detection depth of tumors in vivo. We removed and minced SCC-7 tumors into small pieces of ∼1 mm 3 , and then opened up the abdominal cavity under pentobarbital anesthesia and glued four pieces of tumors ∼4 mm apart each other on the backside of the liver. A week later, we performed the phosphorescence imaging by BTPHSA and BTP. When we used an excitation/emission wavelength of 575 to 605 nm/645 nm, we could detect four BTPHSA phosphorescent images from the four tumors, although Figure 4 . Imaging of BTPH with a longer excitation and emission wavelength. A, shift of excitation and emission to a longer wavelength range. Left, π-electron system-extended probes, BTPH and BTPHSA. Chemical structure was drawn with π-electron system-extended phenyl rings (red). Right, excitation [black line and its ×20 blow-up (blue)] and emission (red) spectra of BTPH and BTPHSA in DCE at room temperature. B, in vivo imaging for BTP-and BTPHSA-marked tumors. SCC-7 tumor was grown in the subcutaneous region. The tumor-bearing nude mice were injected with 250 nmol BTP or BTPHSA in a similar manner to the BTP-imaging experiment in Fig. 3 . Phosphorescence was observed using Maestro for BTP and BTPHSA by excitation/ emission of 445 to 490 nm/580 nm and 575 to 605 nm/645 nm. C, the detection depth with BTPHSA and BTP phosphorescence. SCC-7 tumors were excised and minced into pieces ∼1 mm 3 . The abdominal cavity was opened up and the backside of the liver was exposed. Four pieces of tumors were placed separately, 4 mm from each other, on the backside surface of the liver and were adhered by a surgical glue. The tumor sites were 6 to 7 mm deep from the abdominal skin surface. A week later, BTPHSA and BTP were injected from the tail vein and their phosphorescence images were taken by Maestro. Tumors were grown ∼2 mm in diameter. Left, BTPHSA-marked tumors. Right, BTP-marked tumors. Filters were selected for BTPHSA and BTP as described in B.
each tumor image was a little fuzzy (Fig. 4C) . BTP images were not detected. However, with 445 to 490 nm/580 nm, we could detect neither BTP nor BTPHSA image. The depth of tumor sites on the backside of the liver was measured 6 to 7 mm from the abdominal skin surface. Thus, we suggest that a longer wavelength-shifted BTP analogue improves the detection depth of tumors in living animals.
Tissue and cellular localization of BTP
In the first and second sections of Results, we assumed that BTP is transferred from albumin to the cells for its cellular uptake. To verify intracellular BTP localization, we used two methods: morphologic examination and phosphorescence lifetime measurement. For morphologic examination at the cellular level, we used HeLa cells culturing with 10% FBS. Cellular BTP localization seemed to be limited to the cytoplasm and not to the nucleus (Fig. 2B) . We examined color merging using green-colored endoplasmic reticulum (ER)-specific probe ER tracker and mitochondria-specific probe Mitotracker. We observed a merged yellow color between BTP and ER tracker (Fig. 5A, top) . However, no green-colored Mitotracker merged with BTP (Fig. 5A, bottom) . Organelle markers used were ER tracker and Mito tracker, which selectively stain ER and mitochondria, respectively. Right, merged pictures. Scale bars, 10 μm. B, in vivo phosphorescence spectra and lifetime measurements. Top, phosphorescence spectra of BTP in tumors and normal tissues in a tumor-bearing nude mouse. Bottom, their decay curves monitored at 620 nm. The phosphorescence decay profiles could be fitted to single exponential functions with lifetimes of 2.9 and 1.7 μs, respectively, for the tumor moiety and the normal tissue.
Thus, BTP seems to have efficient access to the ER in the cytoplasm.
For tissue examination, we used the Olympus in vivo laser scanning microscope IV100. Initially, we applied this microscope to the tumor tissue, but could not detect a clear view, perhaps due to the less sensitive visualizing mechanism. However, after anesthetic death of the mouse, we could detect a relatively good view on the liver, which is the BTP excretion route to bile juice. BTP was indicated as green, whereas microvessels were marked with red AngioSense-750 ( Supplementary Fig. S5 ). BTP appeared to be trapped in cell bodies, but it did not remain in microvessels and interstitial spaces. Thus, we suggest that BTP is transported to the cell bodies and is localized mostly to the ER.
Another method was performed with a phosphorescence lifetime measurement. The excitation light (337 nm) from a nanosecond-pulsed discharge lamp filled with nitrogen gas was collimated to the mouse tumor or normal tissues and the phosphorescence at 620 nm was detected by a photomultiplier tube after passing through a monochromator. The phosphorescence decay profiles could be fitted to single exponential functions with lifetimes of 2.9 and 1.7 μs for the tumor and the normal tissue, respectively (Fig. 5B) . If we assume that BTP exists in the cell membrane, pO 2 for the tumor and the normal tissues can be evaluated to be 13 and 33 mmHg, respectively, using the k q value (1.2 × 10 4 mmHg
and τ p 0 = 5.3 μs in the DMPC membrane. These values are consistent with those measured by an oxygen electrode (Supplementary Table S1 ). Judging from the extremely small quenching rate constant (5.0 × 10 2 mmHg
) for BTP bound to albumin, such a remarkable oxygen quenching will be impossible to occur if BTP exists binding to albumin in microvessels. Thus, we conclude that BTP is localized inside the cells and the longer lifetime of BTP in tumors than that in normal tissues clearly reflects a low oxygen concentration in the tumors.
Discussion
We showed a promising potential of the phosphorescent iridium complex, BTP analogues, for hypoxic tumor imaging. Using the oxygen-quenching feature, tumors were visible even 5 minutes after the BTP injection (Fig. 3) . The luminescent region became widespread over the tumor profile 1 to 2 hours after the BTP injection and disappeared within 24 hours (Supplementary Fig. S3B ). BTP analogues are distributed systemically to the whole body and emit phosphorescence where the oxygen supply is insufficient because simple skin ligation immediately displayed red phosphorescence ( Supplementary Fig. S3A ). In this sense, BTP analogues are distinct in its luminescence emission from other tumordetecting probes, such as nitroimidazole, Cu(II)-ATSM, and 18 F-fluorodeoxyglucose. In other words, BTP analogues are hypoxia-sensing emitters, whereas the above three are hypoxia-accumulating emitters. For example, nitroimidazole accumulates in a hypoxic tissue in which the nitro residues are reduced by the lack of sufficient oxygen and the reduced form is thought to bind to macromolecules (6, 21) . Cu(II)-ATSM is also reduced in hypoxic tissue to release Cu(I), which is thought to bind to macromolecules (22) . These probes should be radiolabeled for PET and require costtaking PET facilities and equipment.
Although BTP was distributed over the profile of a tumor (Fig. 3) , it was questionable whether BTP is localized intracellularly to tumors or whether it stays in the tumor microvessels by binding to albumin. By morphologic examination and phosphorescence lifetime measurement, we found that BTP is localized to tumor cells, especially to ER organelles, and does not stay in the microvessels (Supplementary Fig. S5;  Fig. 5 ). In this sense, BTP analogues are distinct from other phosphors such as dendrimer-coated porphyrins (14, 16, 23) . BTP analogues are small phosphors with a molecular mass of 700 to 800 Da. In contrast, dendrimer-coated porphyrins are large in size, over 2 kDa, and remain in tumor microvessels or interstitial space without penetrating into cells (14, 16, 23) .
Luminescent probes have an inevitable drawback, that is, their weak tissue penetration capacity, which is reportedly a magnitude of centimeters by near-IR wavelength light (24) . The phosphorescence of BTP appears in the red to near-IR region (>600 nm), whereas the excitation wavelength is limited to the visible light region (445-490 nm). However, a great advantage of the iridium complexes lies in their facility in chemical modifications of the ligands. The ligand molecules of BTP consist of two benzothienyl-pyridinato groups and an acetylacetone as an ancillary ligand. The spectral properties of BTP are determined almost exclusively by the benzothienylpyridinato groups. On the other hand, the acetylacetone moiety in BTP analogues scarcely influences the spectral properties of the complex. We can, therefore, improve the absorption and emission properties of BTP to BTPH and BTPHSA by modifying this moiety (Fig. 4A) . The penetration limit of BTPH was extended to~1.0 mm deep (Supplementary Fig. S4B ). Consistently, we were able to detect and count tumor numbers situated on the backside of the liver 6 to 7 mm deep from the abdominal skin surface (Fig. 4C) . Thus, BTP imaging is applicable when tumors are situated relatively near the tissue surface such as gastrointestinal mucosal to submucosal layers. Because the detection limit of tumor size was estimated to be ∼2 mm in diameter ( Supplementary  Fig. S4A ), microadenoma and microcancer seem to be a target of BTP analogue imaging. We emphasize that BTP analogues are easily modified to better probes with a longer wavelength and appropriate water solubility. Furthermore, BTP analogues seem to be safe based on preliminary toxicity tests (data not shown). Therefore, we suggest that BTP analogues have practical feasibility for tumor hypoxia imaging.
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